Suchergebnisse - Peter Staib
- Treffer 1 - 20 von 36
- Zur nächsten Seite
-
1
-
2
Genetic advances in dermatophytes von Maria Grumbt, Michel Monod, Peter Staib
Veröffentlicht 2011Artigo -
3
-
4
-
5
Candida species Rewired Hyphae Developmental Programs for Chlamydospore Formation von Bettina Böttcher, Christine Pöllath, Peter Staib, Bernhard Hube, Sascha Brunke
Veröffentlicht 2016Artigo -
6
-
7
-
8
WSG ADAPT – adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a pros... von Daniel Hofmann, Ulrike Nitz, Oleg Gluz, Ronald Kates, Timo Schinkoethe, Peter Staib, Nadia Harbeck
Veröffentlicht 2013Artigo -
9
-
10
-
11
Gene Expression Profiling in the Human Pathogenic Dermatophyte <i>Trichophyton rubrum</i> during Growth on Proteins von Christophe Zaugg, Michel Monod, Johann Weber, Keith Harshman, Sylvain Pradervand, Jérôme Thomas, Manuel Bueno Sánchez, Karin Giddey, Peter Staib
Veröffentlicht 2008Artigo -
12
Small Molecule Inhibitors of Wnt/β-Catenin/Lef-1 Signaling Induces Apoptosis in Chronic Lymphocytic Leukemia Cells In Vitro and In Vivo von Rajesh Kumar Gandhirajan, Peter Staib, Katharina Minke, Iris Gehrke, Günther Plickert, Axel Schlösser, E. Schmitt, Michael Hallek, Karl‐Anton Kreuzer
Veröffentlicht 2010Artigo -
13
Patients with <i>de novo</i> acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients von Claudia Schoch, Torsten Haferlach, Detlef Haase, Christa Fonatsch, Helmut Löffler, Brigitte Schlegelberger, Peter Staib, Maria Cristina Sauerland, Achim Heinecke, Thomas Büchner, Wolfgang Hiddemann
Veröffentlicht 2001Artigo -
14
Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marke... von Susanne Schnittger, Claudia Schoch, Martin Dugas, Wolfgang Kern, Peter Staib, Christian Wuchter, Helmut Löffler, Cristina M. Sauerland, Hubert Serve, Thomas Büchner, Torsten Haferlach, Wolfgang Hiddemann
Veröffentlicht 2002Artigo -
15
Factors Supporting Cysteine Tolerance and Sulfite Production in Candida albicans von Florian Hennicke, Maria Grumbt, Ulrich Lermann, Nico Ueberschaar, Katja Palige, Bettina Böttcher, Ilse D. Jacobsen, Claudia Staib, Joachim Morschhäuser, Michel Monod, Bernhard Hube, Christian Hertweck, Peter Staib
Veröffentlicht 2013Artigo -
16
Molecular subtypes of NPM1 mutations have different clinical profiles, specific patterns of accompanying molecular mutations and varying outcomes in intermediate risk acute myeloid... von Tamara Alpermann, Susanne Schnittger, Christiane Eder, Frank Dicker, Manja Meggendorfer, Wolfgang Kern, C Schmid, Carlo Aul, Peter Staib, Clemens‐Martin Wendtner, N. Schmitz, Claudia Haferlach, Torsten Haferlach
Veröffentlicht 2015Carta -
17
A novel hierarchical prognostic model of AML solely based on molecular mutations von Vera Grossmann, Susanne Schnittger, Alexander Kohlmann, Christiane Eder, Andreas Roller, Frank Dicker, Christoph Schmid, Clemens‐Martin Wendtner, Peter Staib, Hubert Serve, Karl‐Anton Kreuzer, Wolfgang Kern, Torsten Haferlach, Claudia Haferlach
Veröffentlicht 2012Artigo -
18
Basic Fibroblast Growth Factor Controls Migration in Human Mesenchymal Stem Cells von Annette Schmidt, Dennis Ladage, Timo Schinköthe, Ursula Klausmann, Christoph Ulrichs, Franz‐Josef Klinz, Klara Brixius, Stefan Arnhold, Biren Desai, Uwe Mehlhorn, Robert H. G. Schwinger, Peter Staib, Klaus Addicks, Wilhelm Bloch
Veröffentlicht 2006Artigo -
19
Fludarabine in Combination With Alemtuzumab Is Effective and Feasible in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia: Results of a Phase II Trial von Thomas Elter, Peter Borchmann, H. Schulz, Marcel Reiser, Sven Trelle, Roland Schnell, Markus Jensen, Peter Staib, Timo Schinköthe, H. Stützer, Jürgen Rech, Martin Gramatzki, Walter E. Aulitzky, Ibrahim Hasan, Andreas Josting, Michael Hallek, Andreas Engert
Veröffentlicht 2005Artigo -
20
Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response von Sibylle Loibl, Andreas Schneeweiß, Jens Huober, Michael Braun, Julia Rey, Jens‐Uwe Blohmer, Jenny Furlanetto, D M Zahm, Claus Hanusch, Jörg Thomalla, Christian Jackisch, Peter Staib, Theresa Link, Kerstin Rhiem, Christine Solbach, Peter A. Fasching, Valentina Nekljudova, Carsten Denkert, Michael Untch
Veröffentlicht 2022Artigo
Suchwerkzeuge:
Ähnliche Schlagworte
Biology
Genetics
Medicine
Gene
Internal medicine
Oncology
Microbiology
Cancer research
Immunology
Biochemistry
Leukemia
Myeloid leukemia
Candida albicans
Chemotherapy
Gene expression
Breast cancer
Cancer
Cell biology
Gastroenterology
Chronic lymphocytic leukemia
Corpus albicans
Cyclophosphamide
Lymphoma
Mutant
Physics
Chemistry
Chromosome
Clinical trial
Dermatophyte
Enzyme